Stockscreener 앱 받기
312.17
1.31%
-4.13
시간 외 거래:
312.17
전일 마감가:
$316.30
열려 있는:
$314.18
하루 거래량:
706.63K
Relative Volume:
0.80
시가총액:
$22.05B
수익:
$3.22B
순이익/손실:
$542.70M
주가수익비율:
41.73
EPS:
7.4805
순현금흐름:
$458.00M
1주 성능:
-1.27%
1개월 성능:
+3.82%
6개월 성능:
+14.34%
1년 성능:
+49.09%
1일 변동 폭
$311.46
$316.74
1주일 범위
$308.23
$324.35
52주 변동 폭
$206.19
$330.88
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
312.17 | 22.35B | 3.22B | 542.70M | 458.00M | 7.4805 |
ISRG
Intuitive Surgical Inc
|
402.30 | 146.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.43 | 40.04B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.28 | 32.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.19 | 30.23B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
182.82 | 27.04B | 5.54B | 1.52B | 1.74B | 10.37 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion - Yahoo Finance
West Pharmaceutical Names Michel Lagarde Next CEO - The Globe and Mail
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion - The Motley Fool
West Pharmaceutical Services Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Q1 2026 Life Sciences Earnings Review: PacBio vs. West Pharmaceutical PerformanceNews and Statistics - IndexBox
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating - Moomoo
West Appoints Michel Lagarde a President and CEO - Contract Pharma
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - TradingView
WST Reiterated by Stephens & Co. -- Price Target Maintained at $360 - GuruFocus
West Pharmaceutical Services (WST) Announces Leadership Transiti - GuruFocus
West Pharmaceutical Services Appoints Michel Lagarde as President and CEO Effective August 31, 2026 - Minichart
Is Wall Street bullish or bearish on West Pharmaceutical Services stock? - MSN
West Pharmaceutical (WST) Names Michel Lagarde as New CEO - GuruFocus
West Pharmaceutical Services names Michel Lagarde as next CEO, effective Aug. 31 - MSN
Wolfe Research initiates West Pharmaceutical stock with outperform rating By Investing.com - Investing.com India
West Pharma names former Thermo Fisher executive Lagarde as CEO - MSN
Wolfe Research initiates West Pharmaceutical stock with outperform rating - Investing.com
West Pharmaceutical names Michel Lagarde as next CEO _newTouch_By Investing.com - Investing.com South Africa
West Pharmaceutical Services Inc. stock underperforms Monday when compared to competitors - MarketWatch
West Pharmaceutical names Michel Lagarde as next CEO By Investing.com - Investing.com Australia
Michel Lagarde to lead West Pharmaceutical (NYSE: WST) as new CEO - Stock Titan
West Pharmaceutical Services, Inc. Announces CEO Changes, Effective August 31, 2026 - marketscreener.com
West Pharmaceutical Services (WST): A Healthcare Innovator with an 8.61% Upside Potential - DirectorsTalk Interviews
At US$323, Is West Pharmaceutical Services, Inc. (NYSE:WST) Worth Looking At Closely? - Moomoo
Morgan Stanley Adjusts West Pharmaceutical Services PT to $325 From $315, Keeps Equalweight Rating - Moomoo
WST Stock Chart | WEST PHARMACEUTICAL SERVICES (NYSE:WST) - ChartMill
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Here's what to expect from West Pharmaceutical's next earnings report - MSN
West Pharmaceutical Services Inc. stock outperforms competitors despite losses on the day - MarketWatch
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now - TradingView
Is Wall Street Bullish or Bearish on West Pharmaceutical Services Stock? - Barchart.com
A Look At West Pharmaceutical Services (WST) Valuation After Recent Share Price Momentum - Yahoo Finance
West Pharmaceutical Services, Inc. (WST) Stock Analysis: A Healthcare Giant with Notable Growth Potential - DirectorsTalk Interviews
WST Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
West Pharma fully restores operations after cyber attack - MSN
West Pharmaceutical Services (NYSE:WST) Shows Explosive Potential with Perfect Minervini Trend Template and Accelerating Growth - ChartMill
West Pharmaceutical Services Gains Spotlight In S&P 500 Momentum - Kalkine Media
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
West Pharmaceutical restores operations after cyberattack - Plastics News
Analysts Are Bullish on Top Healthcare Stocks: EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:EBR), West Pharmaceutical Services (WST) - The Globe and Mail
A Look at West Pharmaceutical Services Inc (WST) After 3.5% Gain -- GF Value $359.79 vs Price $316.13 - GuruFocus
West Pharmaceutical Shares Rise After Update on Restoration of Core Enterprise Systems Following Cyberattack - Moomoo
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - TradingView
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now - Zacks Investment Research
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast - 104.1 WIKY
Cyber incident update: West Pharmaceutical (NYSE: WST) restores operations - Stock Titan
Trump's Stock Picks Perfectly Timed With New Medicare Rules: ReportEli Lilly (NYSE:LLY) - Benzinga
West Pharma drops after cyber attack - MSN
Trump bought stock in drugmaker as his government boosted its obesity drugs - Fierce Pharma
S&P 500 gains and losses today: West Pharmaceutical Services stock surges; Dow, LKQ shares fall - MSN
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.94%
0.78%
자본화:
|
볼륨(24시간):